National Comprehensive Cancer Network

Educational Events & Programs

NCCN 9th Annual Congress:
Hematologic Malignancies™

September 19 – 20, 2014

New York Marriott Marquis
New York, New York


Register Now

Overview

Treatment of hematologic malignancies is increasingly complex. Issues relating to pathology, transplantation, and various new therapies require oncologists and hematologists to stay abreast of breakthrough advances. In addition, targeted therapies and oral treatments bring the latest benefits to patients. This Congress focuses on the new approaches that have been incorporated into patient management, including the use of drugs, biologics, and diagnostics.

The NCCN 8th Annual Congress: Hematologic Malignancies™ took place September 20 – 21, 2013 in New York, NY. Accredited materials from this congress are available through the NCCN Continuing Education Portal.

Recorded presentations featuring Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, and Non-Hodgkin’s Lymphomas from the NCCN 19th Annual Conference: Advancing the Standard of Cancer Care™ held March 13 – 15, 2014 in Hollywood, FL are also available through the NCCN Continuing Education Portal.


Agenda*


Friday, September 19, 2014
4:30 – 6:00 PM Registration, Exhibits, and Refreshments

6:00 – 6:15 PM Opening Remarks
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

6:15 – 7:00 PM Optimal Management of CML without Breaking the Bank
Neil P. Shah, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center

7:05 – 7:35 PM

Molecular Monitoring in CML: Known Knowns, Known Unknowns, and Unknown Unknowns
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

7:40 – 8:10 PM Current Management of Adult ALL
Joseph C. Alvarnas, MD
City of Hope Comprehensive Cancer Center


8:15 – 8:45 PM Chimeric Antigen Receptor (CAR) Modified T Cells for ALL
Renier J. Brentjens, MD, PhD
Memorial Sloan Kettering Cancer Center


Saturday, September 20, 2014
7:00 – 8:00 AM Registration, Exhibits, and Breakfast

8:00 – 8:05 AM Opening Remarks
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

8:05 – 8:35 AM Management of Hodgkin Lymphoma in the Elderly
Jane N. Winter, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University


8:40 – 9:10 AM

Targeted Therapy in Indolent Lymphoma
Jeremy S. Abramson, MD
Massachusetts General Hospital Cancer Center

9:15 – 9:45 AM Debate: Is there a Role for Upfront Transplant in the Current Management of Symptomatic Multiple Myeloma?
Kenneth C. Anderson, MD
Dana-Farber/Brigham and Women's Cancer Center

Sergio A Giralt, MD
Memorial Sloan Kettering Cancer Center

9:50 – 10:20 AM The Continuum of MGUS and Smoldering Myeloma: When to Treat?
C. Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center

10:20 – 10:35 AM Break and Exhibits

10:35 – 11:05 AM Molecular Prognostication in CLL from FISH to Next Generation Sequencing: Implications for Clinical Management
Jennifer R. Brown, MD, PhD
Dana-Farber/Brigham and Women's Cancer Center

11:10 – 11:40 AM Changing Paradigms in the Management of CLL
William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center

11:40 AM – 12:50 PM Lunch and Exhibits

11:45 AM – 12:45 PM

Satellite Symposium: Recent Developments in Treating Indolent Non-Hodgkin's Lymphoma**
Steven M. Horwitz, MD
Memorial Sloan Kettering Cancer Center

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Jointly sponsored by NCCN and Clinical Care Options


12:50 – 1:20 PM

Updates on the Prevention and Treatment of Cancer-Related Infections
Laura Zitella, RN, MS, ACNP-BC
Stanford Cancer Institute

1:25 – 1:55 PM Myeloid Growth Factors Revisited
Jeffrey Crawford, MD
Duke Cancer Institute

2:00 – 2:30 PM Evolving Therapy of Mantle Cell Lymphoma: Is There Still a Role for Upfront Transplant?
Issa F. Khouri, MD
The University of Texas MD Anderson Cancer Center

2:35 – 3:05 PM Diffuse Large B Cell Lymphoma: Treatment Beyond R-CHOP
Leo I. Gordon, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

3:05 – 3:20 PM Break and Exhibits

3:20 – 3:50 PM Debate: Follicular Lymphoma and the Role of Maintenance Therapy
Richard I. Fisher, MD
Fox Chase Cancer Center

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

3:55 – 4:25 PM Role of Molecular Advances in the Classification and Prognosis of MDS
Peter L. Greenberg, MD
Stanford Cancer Institute

4:30 – 5:00 PM AML: Current Management
Eunice S. Wang, MD
Roswell Park Cancer Institute

5:00 PM Closing Remarks
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

   

*This agenda is subject to change. Faculty will be updated as confirmed.

**Pre-registration for this satellite lunch program is not required. This program is available to attendees on a first-come, first-seated basis.



Accreditation
This congress is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for case managers, nurses, pharmacists, and other health care professionals. Please refer to the complete accreditation details for more information.

Fees
Reserve your seat by Friday, August 15, 2014 to receive the Early Bird Registration rate. Please refer to the complete fee details for more information.

  • Special Discount
    As a benefit of membership, NCCN extends a 20% discount off the registration fee to staff employed at NCCN Member Institutions. For a list of NCCN Member Institutions, please visit: http://www.nccn.org/members/network.asp. Please contact Liz Rieder, Senior Registration Manager, at rieder@nccn.org to learn how to apply this discount.
  • Fellows Registration
    Fellows registering by Friday, August 15, 2014 may receive complimentary registration. Fellows must provide a letter on institution letterhead from their Director stating that they are a Fellow in good standing.

Accommodations
NCCN has a limited number of rooms reserved for registered attendees for the nights of Friday, September 19th and Saturday, September 20th at a discounted rate of $294, per night. Please refer to the complete accommodations details for more information.  

Supporters
This congress is supported by educational grants from CELGENE CORPORATION; Millennium: The Takeda Oncology Company; Novartis Oncology; Pfizer; and Sigma-Tau Pharmaceuticals, Inc.  
(As of August 26, 2014)


Exhibitor Information

Organizations who are interested in exhibiting at NCCN programs are encouraged to contact Jennifer Tredwell, Director, Marketing.

Exhibit Application

Exhibit Floor Plan

Exhibitor Show Services Kit


Please check back often for the most up-to-date information. Please contact 866.788.NCCN (6226) or send an e-mail if you have additional questions.